MediciNova, Inc. (MNOV)
$1.47-2.00%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $72M
- Beta
- 0.61
- P/E (TTM)
- -6.77
- Short % float
- 0.80%
- Days to cover
- 1.0
- SI change
- -9.5%
- 1W
- -8.70%
- 1M
- -27.23%
- vs SPY 1W
- -8.56%
- vs SPY 1M
- -29.73%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 3
- GROWTH
- 8
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-15.9%
REV YoY-
ROE-26.5%
EPS YoY-
ROA-26.6%
GROSS42
OP-1287
NET-1168
[VALUATION]
P/E TTM-6.77
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B1.94
P/FCF-
EV/EBITDA-4.30
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.31
ALTMAN Z-
CURR RATIO8.75
ND/EBITDA-
BETA0.61
Company news
FAQ
- What is LOPJLB’s current signal on MNOV?
- LOPJLB’s latest quantitative signal on MediciNova, Inc. (MNOV) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MNOV in?
- MediciNova, Inc. (MNOV) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does MediciNova, Inc. (MNOV) do?
- MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurologi…